Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid (TXA2014-15)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02229292|
Recruitment Status : Completed
First Posted : September 1, 2014
Last Update Posted : March 10, 2017
Purpose of the study:
- To evaluate the effect of tranexamic acid (TXA) of intraoperative blood loss in patients subjected to bi-maxillary orthognathic surgery
- To evaluate the potential effect of TXA on fibrin structure
- To evaluate the potential effect of TXA of binding of plasminogen to fibrin
- To evaluate the potential effect of TXA on postoperative edema formation.
H0: Intraoperative bleeding cannot be significantly reduced by preoperative administration of tranexamic acid
H0,1: Postoperative edema cannot be significantly reduced by preoperative administration of tranexamic acid
|Condition or disease||Intervention/treatment||Phase|
|Intraoperative Bleeding Postoperative Edema||Drug: Tranexamic Acid Drug: Saline||Phase 4|
The study population consists of patients referred to simultaneous mandibular and maxillary osteotomy at the Department of Oral and Maxillofacial Surgery, Hospital of South West Denmark in 2014.
Hundred patients (50 men and 50 women) will be enrolled in the study. Reportedly, the mean intraoperative blood loss in the placebo group is expected to be 436 ml with a standard deviation of 208 ml. The difference in blood loss between the TXA-group and the placebo group to be detected is 100 ml. The dropout frequency is estimated to 10%. To fulfil these assumptions a minimum of 40 patients should be included in each group to reach a power of 0.8 and an alpha of 0.05. In order to accommodate an even gender distribution a block randomization is performed resulting in the randomization of 100 patients.
The patients will be randomized to receive blindly either 10 ml tranexamic acid (100 mg/ml) (Pfizer, Ballerup, Denmark) or 10 ml saline (9mg/ml) preoperatively. Intraoperative blood loss will be determined by deducting the total volume of irrigation fluids from the volume of the contents of the surgical suction device. Postoperative edema formation will be determined by 3D surface scanning and volumetric analysis will be carried out in the "Landmarker" software.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||104 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.|
|Study Start Date :||August 19, 2014|
|Actual Primary Completion Date :||September 26, 2016|
|Actual Study Completion Date :||September 26, 2016|
Active Comparator: Tranexamic acid
The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
Drug: Tranexamic Acid
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.
Other Name: Tranexamsyre "Pfizer", D.SP.NR.: 22646, ATC code: B 02 AA 02
Placebo Comparator: Saline
The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.
Other Name: Natriumklorid "B. Braun", D.SP.NR.: 6856, ATC code: V 07 AB
- Intra-operative bleeding volume (ml) [ Time Frame: Within 10 minutes after ended surgery ]
- Change in hemostatic profile [ Time Frame: Baseline, 5.5 hours, 48 hours and 4 months postoperatively ]Changes in the hemostatic profile measured through thrombelastography, thrombin generation test and fibrin structure analysis.
- Change in inflammatory profile [ Time Frame: Baseline, 5.5 hours, 48 hours and 4 months postoperatively ]Changes in the inflammatory profile are investigated through measures of surface induced activation, inflammation and plasminogen binding.
- Postoperative edema formation [ Time Frame: 48 hours and 4 months postoperatively ]The degree of postoperative swelling in connection with TXA /or not, is determined by non-invasive 3D face scans and quantified using the "Landmarker" software. Scans are carried out along with the 3rd and 4th blood samples, 48 hours and 4 months postoperatively.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02229292
|Hospital of South West Denmark|
|Esbjerg, Denmark, 6700|
|Principal Investigator:||Jesper J Olsen, DDS||Hospital of South West Denmark|